Esperion Therapeutics (ESPR) Stock: Gaining On Strong Clinical Data


Esperion Therapeutics Inc (NASDAQ: ESPR) is having an incredibly strong start in the pre-market hours this morning, and for good reason. The company released top-line data from a key clinical trial, and as you could imagine the data was overwhelmingly positive. This led to excitement among investors, sending the stock toward the top and prompting our partners at Trade Ideas to alert us to the gains. At the moment (8:34), ESPR is trading at $52.45 per share after a gain of $7.28 per share or 16.12% thus far today.

ESPR Releases Positive Clinical Data

As mentioned above, Esperion Therapeutics is having a strong time in the pre-market this morning after releasing overwhelmingly positive clinical data. The data came from the company’s Phase 2 clinical study, assessing the combination treatment, Bempedoic acid/ezetimibe combined with atorvastatin 20mg in patients with hypercholesterolemia. In their press release, the company said that the treatment proved to be a success, producing a clinically relevant 48% reduction in hsCRP and was observed to be safe and well-tolerated. In a statement, Tim M. Mayleben, president and CEO at ESPR, had the following to offer…

Patients in this study experienced nearly a 100mg/dl drop in their LDL-C levels on the combo plus atorvastatin. These highly positive study results of the combination therapy demonstrate very robust and remarkably consistent LDL-C lowering with what appears to be optimal safety and tolerability… Next year we intend to initiate additional studies to further explore these complementary oral therapies and provide physicians and players with an even deeper understanding of how our bempedoic acid-based products may be used in combination with maximally-tolerated statin therapy. Our goal remains to leverage the bempedoic acid franchise to provide physicians with the flexibility to utilize multiple convenient, cost-effective, once-daily, oral therapies to treat the vast majority of patients with elevated LDL-C.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ESPR. In particular, we’re interested in following the ongoing work with regard to the combination treatment surrounding atorvastatin. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here